Navigation Links
New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
Date:2/14/2008

New Mexico Department of Veterans Services Partners with New Mexico Tech

and Biomoda, Inc.

ALBUQUERQUE, N.M., Feb. 14 /PRNewswire-FirstCall/ -- The New Mexico Institute of Mining and Technology (New Mexico Tech) and Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), have partnered with the New Mexico Department of Veterans Services (DVS) to conduct a $350,000 clinical study using proprietary testing technology for detection of early lung cancer in the state's veterans.

The $350,000 clinical program will be administered by New Mexico Tech, a science and engineering research university in Socorro. Biomoda, a biotech company focusing on very early cancer detection technology, through its Albuquerque office, will conduct the first year of the program using its patented non-invasive diagnostic technology for cost-efficient screening of early stage lung cancer in large populations. New Mexico Tech and the New Mexico Department of Veterans Services will oversee the clinical program.

"Early detection is critical to surviving lung cancer," said New Mexico Tech President Dr. Daniel H. Lopez. "Further enhancement and validation of these technologies will significantly impact the way we diagnose and treat lung cancer throughout the world. New Mexico Tech is excited to play a significant role on this project."

Biomoda's technology is based on a patented application that identifies cancerous or aberrant cells from samples of lung sputum. Cancerous cells glow red under fluorescent light and can be detected under a microscope. The technology is non-invasive and designed for cancer screening of large populations at a reasonable cost.

"By supporting this study, our state's public officials have illustrated the importance of caring for our veterans and providing the opportunity to be diagnosed, treated, and potentially cured of lung cancer by catching it in the early stages," said John Cousins, President of Biomoda.

Biomoda's team of experts will be dedicated to the year-long clinical study. The team includes representatives from TriCore Laboratories, Averion International, and Quintiles Consulting. The Black Veterans Association of New Mexico will assist with outreach to veterans.

With more than 160,000 people diagnosed every year, lung cancer represents 30 percent of all cancer deaths in the U.S. Veterans have a 25 percent higher risk exposure, incidence and lung cancer mortality rates than civilians.

For more information contact: Jamila Taylor

Calypso Communications

603-431-0816

jtaylor@calypsocom.com


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
Breaking Biology News(10 mins):